Alvotech (DE:Z45)
NASDAQ:Z45
Z45 Stock Chart & Stats
€2.99
€0.70(6.11%)
At close: 4:00 PM EST
€2.99
€0.70(6.11%)
Day’s Range― - ―
52-Week Range€2.52 - €8.54
Previous CloseN/A
Volume0.00
Average Volume (3M)419.00
Market Cap
€1.14B
Enterprise Value€2.62B
Total Cash (Recent Filing)€63.83M
Total Debt (Recent Filing)€1.46B
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 19, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding334,819,820
10 Day Avg. Volume469
30 Day Avg. Volume419
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.02Price Target Upside34.40% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.04
Revenue Forecast (FY)€537.46M
Bulls Say, Bears Say
Bulls Say
Gross Margin StabilityAlvotech reports consistently high gross margins (~60% across 2024–2026). Durable gross profitability supports investment in R&D and commercialization, provides buffer versus pricing pressure in biosimilars, and underpins sustainable EBITDA generation as volumes scale.
Broad Commercial Footprint And PartnershipsA wide geographic reach and strong partner relationships (e.g., Teva, Sandoz distribution deals) give Alvotech durable market access and commercial capabilities. Partner-led commercialization reduces single-market execution risk and accelerates adoption of multiple biosimilars globally.
Integrated Manufacturing Platform And Fujifilm Tie-upOwning an end-to-end biologics platform plus a technology-transfer agreement with Fujifilm strengthens capacity diversification and supply resilience. Adding U.S. manufacturing capacity is a structural advantage for timely launches and reduces single-site regulatory/sourcing risk over the medium term.
Bears Say
High Leverage And Negative EquityMaterial net leverage and negative shareholders' equity constrain financial flexibility and raise refinancing risk. A capital structure weighted to debt increases vulnerability to rate shifts, limits strategic optionality, and elevates the probability that future operations require external funding.
Persistent Cash Burn And Limited LiquiditySustained negative operating and free cash flow means Alvotech depends on financing to fund operations and capex. Limited cash on hand plus ongoing investment requirements increase dilution or refinancing needs and raise execution risk until positive FCF is achieved.
Regulatory Overhang And Throughput-driven VolatilityAddressable but material regulatory observations prompted deliberate production slowdowns, reducing throughput and product margins and causing lumpy revenue (heavy licensing mix). Regulatory timing and manufacturing normalization remain key execution risks for sustained commercial momentum.
Alvotech News
Z45 FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was €2.52 and its highest was €8.54 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is €1.14B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Aug 19, 2026 which is in 59 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on May 06, 2026. The company reported -€0.077 earnings per share for the quarter, missing the consensus estimate of -€0.04 by -€0.037.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.02.
How many shares outstanding does Alvotech have?
Alvotech has 334,819,820 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -€0.077 in its last earnings report, missing expectations of -€0.04. Following the earnings report the stock price went down -11.726%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in DE:Z45
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€4.02 (34.40% Upside)
€4.02 (34.40% Upside)
Blogger Sentiment
Bullish
DE:Z45 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.49%
12-Months-Change
Fundamentals
Return on Equity
35.22%
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Z45 Company Deck
Z45 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong pipeline momentum, rising EBITDA margins, meaningful commercial traction (notably AVT02 market share), a strategic Fujifilm manufacturing partnership and constructive full-year guidance are clear positives. Offsetting these are a material Q1 revenue decline (-20% YoY) and low product margin (11%) driven by deliberate manufacturing slowdowns to address regulatory findings, along with negative operating cash flow, a modest cash balance ($64M) and substantial quarterly interest payments. The company emphasizes derisking for stronger 2027 growth, but near-term financial and regulatory execution risks remain.View all DE:Z45 earnings summariesZ45 Stock 12 Month Forecast
Average Price Target
€4.02
▲(34.40% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Options Prices
Currently, No data available
---